Physician profile
Debra C Keith
NPI 1912012618
$3,272.47
in general payments reported to CMS, 2019-2025
31 companies · $177 in 2025
The $177 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $506 · 2020: $757 · 2021: $777 · 2022: $604 · 2023: $238 · 2024: $213 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $628.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $673.96 | 2019-2025 | |
| Lilly USA, LLC | $315.50 | 2019-2024 | Mounjaro |
| Allergan, INC. | $274.50 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $273.88 | 2019-2025 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.95 | 2019-2023 | Jardiance |
| Amarin Pharma, INC. | $171.42 | 2019-2021 | |
| Novo Nordisk INC | $166.90 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $140.57 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $106.24 | 2019-2023 | Austedo |
| Pfizer INC. | $98.77 | 2019-2021 | |
| Ibsa Pharma INC. | $98.40 | 2022-2023 | Tirosint, Licart |
| Sunovion Pharmaceuticals INC. | $77.68 | 2019-2021 | |
| Amgen INC. | $77.34 | 2019 | |
| Supernus Pharmaceuticals, INC. | $67.18 | 2020-2022 | |
| Corcept Therapeutics | $56.30 | 2024 | Korlym |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $54.94 | 2020-2021 | |
| Shire North American Group INC | $44.63 | 2019 | |
| Abbott Laboratories | $43.11 | 2021-2022 | |
| Glaxosmithkline, LLC. | $40.34 | 2022 | |
| Mannkind Corporation | $35.92 | 2019 | |
| Eisai INC. | $34.25 | 2020 | |
| Janssen Pharmaceuticals, INC | $31.65 | 2024 | Spravato |
| Esperion Therapeutics, INC. | $22.02 | 2020 | |
| Astellas Pharma US INC | $21.00 | 2025 | Veozah |
| Cequr Corporation | $19.61 | 2024 | Cequr Simplicity |
| Biohaven Pharmaceuticals, INC. | $19.05 | 2021 | |
| Hologic Sales and Service, LLC | $16.88 | 2022 | |
| Radius Health, INC. | $16.42 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.10 | 2022 | |
| Adlon Therapeutics L.P. | $14.58 | 2021 | |
| Exeltis, USA INC. | $12.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Keith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.